Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash from Financing Activities (2022 - 2025)

Praxis Precision Medicines (PRAX) has 4 years of Cash from Financing Activities data on record, last reported at $612.5 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 438.4% year-over-year to $612.5 million; the TTM value through Dec 2025 reached $702.2 million, up 36.52%, while the annual FY2025 figure was $702.2 million, 36.52% up from the prior year.
  • Cash from Financing Activities reached $612.5 million in Q4 2025 per PRAX's latest filing, up from $6.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $612.5 million in Q4 2025 and bottomed at $504000.0 in Q2 2022.
  • Average Cash from Financing Activities over 4 years is $87.9 million, with a median of $18.1 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: soared 13724.4% in 2023, then plummeted 86.77% in 2025.
  • A 4-year view of Cash from Financing Activities shows it stood at $5.4 million in 2022, then dropped by 23.41% to $4.1 million in 2023, then skyrocketed by 2657.32% to $113.8 million in 2024, then surged by 438.4% to $612.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $612.5 million in Q4 2025, $6.8 million in Q3 2025, and $28.6 million in Q2 2025.